Abstract
In ulcerative colitis, mucosal healing has clearly been incorporated in the assessment of treatment efficacy. In Crohn’s disease, this concept has only emerged in recent clinical trials with biological therapies. Systemic steroids don’t reliably induce mucosal healing in Crohn’s disease, but purine analogues and anti-TNF agents have a potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti-TNF agents infliximab, adalimumab and certolizumab pegol. For infliximab in Crohn’s disease, mucosal healing has been associated with a reduction in clinical relapses, disease-related hospitalizations and surgeries. On the contrary, the benefit of treating asymptomatic patients with IBD more intensively until they achieve mucosal healing has not been proven. In clinical practice, assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy as well as in patients where treatment discontinuation is being considered.
Keywords: Crohn’s disease, endoscopy, endpoint, ibd, inflammatory bowel disease, medical therapy, mucosal healing, outcome, ulcerative colitis, anti-TNF agents, endpoint, purine analogues.
Current Drug Targets
Title:Medical Therapy and Mucosal Healing
Volume: 13 Issue: 10
Author(s): Marc Ferrante and Gert Van Assche
Affiliation:
Keywords: Crohn’s disease, endoscopy, endpoint, ibd, inflammatory bowel disease, medical therapy, mucosal healing, outcome, ulcerative colitis, anti-TNF agents, endpoint, purine analogues.
Abstract: In ulcerative colitis, mucosal healing has clearly been incorporated in the assessment of treatment efficacy. In Crohn’s disease, this concept has only emerged in recent clinical trials with biological therapies. Systemic steroids don’t reliably induce mucosal healing in Crohn’s disease, but purine analogues and anti-TNF agents have a potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti-TNF agents infliximab, adalimumab and certolizumab pegol. For infliximab in Crohn’s disease, mucosal healing has been associated with a reduction in clinical relapses, disease-related hospitalizations and surgeries. On the contrary, the benefit of treating asymptomatic patients with IBD more intensively until they achieve mucosal healing has not been proven. In clinical practice, assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy as well as in patients where treatment discontinuation is being considered.
Export Options
About this article
Cite this article as:
Ferrante Marc and Van Assche Gert, Medical Therapy and Mucosal Healing, Current Drug Targets 2012; 13 (10) . https://dx.doi.org/10.2174/138945012802429679
DOI https://dx.doi.org/10.2174/138945012802429679 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Targeted Drug Delivery Systems for Lung Macrophages
Current Drug Targets Butyrate and Colorectal Cancer: The Role of Butyrate Transport
Current Drug Metabolism In Vitro Inhibitory Effect of Recombinant Human Calprotectin on Nalm6 Leukemia Cell Line
Anti-Cancer Agents in Medicinal Chemistry Metabolic Effects of Bile Acids in the Gut in Health and Disease
Current Medicinal Chemistry The Concept of Depression as a Dysfunction of the Immune System
Current Immunology Reviews (Discontinued) Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside
Current Drug Targets Analysis of Anticancer Drugs and their Metabolites by Mass Spectrometry
Current Drug Metabolism Regulation of Angiogenesis by the Kallikrein-Kinin System
Current Pharmaceutical Design Chymase Inhibitors
Current Pharmaceutical Design Adjuvant Hormonal Therapy in Women with Early-stage Breast Cancer
Medicinal Chemistry Pharmacological Modulation of Th17
Recent Patents on Inflammation & Allergy Drug Discovery Vesicovaginal Fistula
Current Women`s Health Reviews Strategies to Increase the Oral Bioavailability of Nucleoside Analogs
Current Medicinal Chemistry Thiopurines in Inflammatory Bowel Disease - The Role of Pharmacogenetics and Therapeutic Drug Monitoring
Current Pharmacogenomics Chemokines and their Receptors in Gut Homeostasis and Disease
Current Immunology Reviews (Discontinued) Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Current Concepts on the Genetics and Pharmacogenetics of Inflammatory Bowel Disease: Do they Help in Clinical Management?
Current Genomics Patent Selections
Recent Patents on Biomarkers Enhanced Expression of miR-199b-5p Promotes Proliferation of Pancreatic β-Cells by Down-Regulation of MLK3
MicroRNA